Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity

mouse models. Hence, the first-in-class TRAF6-Ubc13 inhibitor C25-140 expands the toolbox for studying the impact of the ubiquitin system on immune signaling and underscores the importance of TRAF6 E3 ligase activity in psoriasis and rheumatoid arthritis. We propose that inhibition of TRAF6 activity by small molecules represents a promising novel strategy for targeting autoimmune and chronic inflammatory diseases.

Targeting TRAF6 E3 ligase activity with a small-molecule inhibitor combats autoimmunity | Litlas